Morgan Stanley analyst Drew Ranieri initiated coverage with a Hold rating on Organogenesis Holdings (ORGO – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $4.30.
According to TipRanks, Ranieri is a 3-star analyst with an average return of 3.7% and a 50.00% success rate. Ranieri covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, SI-Bone, and Outset Medical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Organogenesis Holdings with a $7.50 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $6.52 and a one-year low of $1.80. Currently, Organogenesis Holdings has an average volume of 1.39M.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ORGO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
Read More on ORGO:
